SPRYNasdaqPharmaceutical PreparationsFiscal year ends December 31
ARS Pharmaceuticals, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$4.23+0.21 (+5.22%)
Close on Oct 19, 2026
- Market cap
- $420.09M
- P/E (TTM)
- –
- Dividend yield
- –
ARS Pharmaceuticals, Inc. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | % of revenue | YoY |
|---|---|---|---|---|---|
| Product revenue, net | $72.19M | $7.26M | $0 | 85.7% | +895.1% |
| Revenue under collaboration agreements [Member] | $9.72M | $81.53M | $30.00K | 11.5% | -88.1% |
| Revenue under supply agreements | $2.37M | $365.00K | $0 | 2.8% | +549.3% |
By region
| Revenue | FY2025 | FY2024 | FY2023 | % of revenue | YoY |
|---|---|---|---|---|---|
| United States | $72.19M | $7.26M | – | 85.7% | +895.1% |
| Rest of World [Member] | $12.09M | $81.89M | – | 14.3% | -85.2% |
From the segment and revenue-disaggregation notes of ARS Pharmaceuticals's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.